1 – 10 of 47
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
(
- Contribution to journal › Article
- 2014
-
Mark
Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.
(
- Contribution to journal › Article
-
Mark
High-Dose Chemotherapy with Stem Cell Rescue in the Primary Treatment of Metastatic and Pelvic Osteosarcoma: Final Results of the ISG/SSG II Study
(
- Contribution to journal › Article
-
Mark
Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib
(
- Contribution to journal › Article
-
Mark
Gastrointestinal Stromal Tumor: A Method for Optimizing the Timing of CT Scans in the Follow-up of Cancer Patients.
(
- Contribution to journal › Article
- 2013
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis.
(
- Contribution to journal › Article
- 2012
-
Mark
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor : A Randomized Trial
(
- Contribution to journal › Article
-
Mark
Adjuvant therapy in primary GIST: state-of-the-art
(
- Contribution to journal › Scientific review
-
Mark
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation
(
- Contribution to journal › Article